Merck buys rights to heart disease drug in latest China deal
Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, ...
Merck Will Pay Up to $2 Billion for Chinese Heart Drug
Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...
Hosted on MSN1mon
Merck & Co., Inc. (MRK): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against ...
Harvard Business School7y
Strategy in the Twenty-First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. (TN)
Collis, David J. "Strategy in the Twenty-First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. (TN)." Harvard Business School Teaching Note 713-450, March 2013.